Exabis Library
Welcome to the e-CCO Library!
P502: Persistence of remission amongst patients with inflammatory bowel disease after adalimumab therapy is stopped: economic and clinical implications
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P502: Ulcerative colitis patients on vedolizumab lacking response at induction phase continue to improve over the first 6 months of treatment
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P503 Changes in clinical use of vedolizumab are driven by lower drug costs and are associated with better outcomes: a real-life single-centre Spanish experience
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P503: Can daily SCCAI measurements over a 6-month period better phenotype the pattern of disease in ulcerative colitis?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P503: Early TNF-antagonist maintenance therapy results in better outcomes than immunomodulators in paediatric Crohn's disease: A multi-centre prospective cohort study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P503: Inflammatory bowel disease video-consulting: a satisfaction survey during the second wave of Covid-19 pandemics
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P503: Rapid point-of-care monitoring of anti-infliximab antibodies in patients with inflammatory bowel disease treated with the reference infliximab or CT-P13 in routine clinical practice
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P503: Tacrolimus vs anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P503: The risk of mild, moderate and severe infections in IBD patients: results from a prospective, multicentre, observational cohort study – PRIQ
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P503: Two year experience with vedolizumab in inflammatory bowel disease patients: results of the ICC case series, a nationwide prospective observational cohort study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P504 Remote cannabis-therapy management platform for IBD patients: performance assessment
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P504: Differences between paediatric and adult inflammatory bowel disease presentation – analysis based on the data from multicenter, prospective cohort observational study assessing safety of anti-TNF therapy – Satimos study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P504: Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with real-world ulcerative colitis: A GETAID multicentre cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P504: Guselkumab, an IL-23p19 subunit–specific monoclonal antibody, binds CD64+ myeloid cells and potently neutralises IL-23 produced from the same cells
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P504: How acceptable is a ‘treat to target’ (T2T) approach to IBD patients in clinical remission?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P504: Prospective analysis of micronutrient status and disease course in Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P504: Stability observations in tacrolimus suppositories
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P504: The variation of faecal calprotectin after 3 months of anti-TNF therapy is a predictor of sustained clinical remission in patients with Crohn's disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P505 Different failure rates after non-medical switching of 744 patients from adalimumab originator to 2 different adalimumab biosimilars at Cambridge University Hospitals, UK: real-world experience
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P505: Early therapeutic drug monitoring after induction therapy with infliximab: correlation with intestinal ultrasound
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM